1278 studies found for:    Kennedy's Disease
Show Display Options
Rank Status Study
21 Recruiting Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Condition: Prostate Cancer
Intervention: Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
22 Terminated
Has Results
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Nilutamide;   Drug: Dasatinib
23 Withdrawn STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: STA9090;   Drug: STA9090 with Dutasteride
24 Recruiting The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: LHRH Agonist
25 Not yet recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
26 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
27 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+), Estrogen Receptor Negative (ER-)/Progesterone Receptor Negative (PgR-) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
28 Recruiting A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: JNJ-56021927
29 Completed Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Condition: Prostate Cancer
Intervention: Genetic: mutation analysis
30 Active, not recruiting CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Conditions: Metastatic Breast Adenocarcinoma;   Breast Cancer
Intervention: Drug: CR1447
31 Terminated
Has Results
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Drug: DHEA;   Procedure: Surgical resection
32 Recruiting AR and ER Imaging in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Other: FDHT-PET scan;   Other: FES-PET scan;   Other: CT-scan;   Other: Bone scintigraphy;   Other: Tumor biopsy
33 Active, not recruiting Phase II Study of GTx024 in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: GTx-024 9mg
34 Not yet recruiting Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz
Condition: Prostate Cancer Metastatic
Interventions: Drug: CABAZITAXEL XRP6258;   Drug: Enzalutamide;   Drug: Abiraterone acetate;   Drug: Prednisone
35 Recruiting Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PROSTVAC-F/TRICOM;   Biological: PROSTVAC-V/TRICOM;   Drug: Enzalutamide (Xtandi)
36 Recruiting Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: PROSTVAC-F/TRICOM;   Biological: PROSTVAC-V/TRICOM;   Drug: Enzalutamide (Xtandi)
37 Not yet recruiting AR-inhibitor Bicalutamide in Treating Patients With TNBC
Condition: Breast Neoplasms
Interventions: Drug: Bicalutamide;   Other: Physician's Choice
38 Unknown  Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
Condition: Prostate Cancer
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: protein analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry
39 Active, not recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Conditions: Recurrent Prostate Carcinoma;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Bicalutamide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis
40 Not yet recruiting Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Condition: Advanced Prostate Cancer
Intervention: Drug: Pelvic DCFPyL PET-MRI fusion or PET/MRI

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years